Stability of busulfan solutions in polypropylene syringes and infusion bags as determined with an original assay

被引:4
作者
Guichard, Nicolas [1 ,2 ]
Bonnabry, Pascal [1 ,2 ]
Rudaz, Serge [2 ]
Fleury-Souverain, Sandrine [1 ]
机构
[1] Geneva Univ Hosp, Geneva, Switzerland
[2] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
关键词
antineoplastic agents; busulfan; chemical precipitation; chromatography; liquid; drug stability; mass spectrometry; QUANTITATIVE ANALYTICAL PROCEDURES; TANDEM MASS-SPECTROMETRY; MARROW-TRANSPLANTATION; SFSTP PROPOSAL; PLASMA BUSULFAN; VALIDATION; HARMONIZATION; STRATEGIES; CELLS;
D O I
10.2146/ajhp160516
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The stability of busulfan solution in 0.9% sodium chloride and stored in polypropylene syringes or infusion bags was evaluated. Methods. Busulfan solutions (0.54 mg/mL) were prepared and transferred to 50-mL polypropylene syringes and 100- and 500-mL polypropylene infusion bags and stored at 2-8 and 23-27 degrees C. Chemical stability was measured using a stability-indicating, ultrahigh performance liquid chromatography coupled to mass spectrometry method. The stability of busulfan was assessed by measuring the percentage of the initial concentration remaining at the end of each time point of analysis. The initial busulfan concentration was defined as 100%. Stability was defined as retention of at least 90% of the initial busulfan concentration. A visual inspection of the samples for particulate matter, clarity, and color without instrumentation of magnification was conducted at each time point of analysis. Results. The visual inspection demonstrated no influence of the storage container when busulfan infusions diluted in 0.9% sodium chloride injection were stored at 23-27 degrees C. No color change or precipitate was observed at this temperature; however, a rapid decrease of the busulfan content in all containers stored at room temperature was observed. Busulfan in syringes was chemically stable for 12 hours, while busulfan in infusion bags (100 and 500 mL) was stable only for 3 hours at 23-27 degrees C. Conclusion. Busulfan 0.54-mg/mL solution in 0.9% sodium chloride injection was physically and chemically stable for 30 hours when stored in 50-mL polypropylene syringes at 2-8 degrees C and protected from light.
引用
收藏
页码:1887 / 1894
页数:8
相关论文
共 26 条
  • [1] [Anonymous], [No title captured]
  • [2] A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry
    Ansari, Marc
    Uppugunduri, Chakradhara Rao S.
    Deglon, Julien
    Theoret, Yves
    Versace, Francois
    Gumy-Pause, Fabienne
    Ozsahin, Hulya
    Dayer, Pierre
    Desmules, Jules
    Daali, Youssef
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2012, 26 (12) : 1437 - 1446
  • [3] Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
    Bornhäuser, M
    Storer, B
    Slattery, JT
    Appelbaum, FR
    Deeg, HJ
    Hansen, J
    Martin, PJ
    McDonald, GB
    Nichols, WG
    Radich, J
    Woolfrey, A
    Jenke, A
    Schleyer, E
    Thiede, C
    Ehninger, G
    Anasetti, C
    [J]. BLOOD, 2003, 102 (03) : 820 - 826
  • [4] Connor TH, 2006, CA CANC J CLIN
  • [5] Desire S, 2013, INDIAN J MED RES, V137, P777
  • [6] Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry
    dos Reis, EO
    Vianna-Jorge, R
    Suarez-Kurtz, G
    Lima, ELD
    Azevedo, DD
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (12) : 1666 - 1674
  • [7] 4-METHANESULFONYLOXYBUTANOL - HYDROLYSIS OF BUSULFAN
    FEIT, PW
    RASTRUPA.N
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1973, 62 (06) : 1007 - 1008
  • [8] Food and Drug Administration, BUS APPR LAB
  • [9] Development and Validation of a Liquid ChromatographyTandem Mass Spectrometry Assay to Quantify Plasma Busulfan
    French, Deborah
    Sujishi, Kirk K.
    Long-Boyle, Janel R.
    Ritchie, James C.
    [J]. THERAPEUTIC DRUG MONITORING, 2014, 36 (02) : 169 - 174
  • [10] HADDOW A, 1953, LANCET, V264, P207